All Japanese Population: Belantamab Mafodotin Plus Pomalidomide and Dexamethasone (Pd) Versus Bortezomib Plus Pd in Relapsed/Refractory Multiple Myeloma
Clinical trial NCT06956170 · ACTIVE_NOT_RECRUITING
Trial details
- NCT number
- NCT06956170
- Sponsor
- GlaxoSmithKline
- Status
- ACTIVE_NOT_RECRUITING
- Phase
- Phase 3
- Study type
- INTERVENTIONAL
- Start date
- 2022-02-10
- Primary completion
- 2024-05-27
- Enrollment
- 21
Track trials programmatically
Sponsors, conditions and status changes through the Atlas API.